Revelation Biosciences, Inc. (NASDAQ:REVB) Short Interest Update

Revelation Biosciences, Inc. (NASDAQ:REVB) was the target of a large drop in short interest during the month of February. As of February 13th, there was short interest totaling 100,079 shares, a drop of 61.2% from the January 29th total of 258,211 shares. Based on an average daily volume of 372,176 shares, the short-interest ratio is currently 0.3 days. Currently, 1.6% of the company’s shares are sold short. Currently, 1.6% of the company’s shares are sold short. Based on an average daily volume of 372,176 shares, the short-interest ratio is currently 0.3 days.

Revelation Biosciences Trading Down 5.7%

Shares of Revelation Biosciences stock opened at $1.33 on Friday. The stock’s fifty day simple moving average is $2.58 and its 200 day simple moving average is $4.98. The company has a market capitalization of $9.18 million, a PE ratio of -0.01 and a beta of -0.11. Revelation Biosciences has a 12 month low of $1.29 and a 12 month high of $46.31.

Revelation Biosciences (NASDAQ:REVB) last announced its quarterly earnings results on Thursday, March 5th. The company reported $15.09 earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.66) by $18.75. Analysts predict that Revelation Biosciences will post -49.33 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC acquired a new stake in shares of Revelation Biosciences during the fourth quarter worth $27,000. Armistice Capital LLC acquired a new stake in shares of Revelation Biosciences in the 3rd quarter valued at about $114,000. Finally, Sabby Management LLC boosted its position in shares of Revelation Biosciences by 214.7% during the third quarter. Sabby Management LLC now owns 207,051 shares of the company’s stock worth $294,000 after buying an additional 141,262 shares during the period. Institutional investors and hedge funds own 12.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e)” rating on shares of Revelation Biosciences in a report on Monday, December 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.